Clinical Practice Guideline for the Management of Infantile Hemangiomas
Top Cited Papers
- 1 January 2019
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 143 (1) , e20183475
Abstract
Infantile hemangiomas (IHs) occur in as many as 5% of infants, making them the most common benign tumor of infancy. Most IHs are small, innocuous, self-resolving, and require no treatment. However, because of their size or location, a significant minority of IHs are potentially problematic. These include IHs that may cause permanent scarring and disfigurement (eg, facial IHs), hepatic or airway IHs, and IHs with the potential for functional impairment (eg, periorbital IHs), ulceration (that may cause pain or scarring), and associated underlying abnormalities (eg, intracranial and aortic arch vascular abnormalities accompanying a large facial IH). This clinical practice guideline for the management of IHs emphasizes several key concepts. It defines those IHs that are potentially higher risk and should prompt concern, and emphasizes increased vigilance, consideration of active treatment and, when appropriate, specialty consultation. It discusses the specific growth characteristics of IHs, that is, that the most rapid and significant growth occurs between 1 and 3 months of age and that growth is completed by 5 months of age in most cases. Because many IHs leave behind permanent skin changes, there is a window of opportunity to treat higher-risk IHs and optimize outcomes. Early intervention and/or referral (ideally by 1 month of age) is recommended for infants who have potentially problematic IHs. When systemic treatment is indicated, propranolol is the drug of choice at a dose of 2 to 3 mg/kg per day. Treatment typically is continued for at least 6 months and often is maintained until 12 months of age (occasionally longer). Topical timolol may be used to treat select small, thin, superficial IHs. Surgery and/or laser treatment are most useful for the treatment of residual skin changes after involution and, less commonly, may be considered earlier to treat some IHs.Keywords
This publication has 149 references indexed in Scilit:
- Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infantsExperimental and Therapeutic Medicine, 2013
- Infantile Hemangioma--Mechanism(s) of Drug Action on a Vascular TumorCold Spring Harbor Perspectives in Medicine, 2011
- Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infantsJournal of the American Academy of Dermatology, 2011
- Conceptual Approach to the Management of Infantile HemangiomasThe Journal of Pediatrics, 2010
- Prospective Study of Spinal Anomalies in Children with Infantile Hemangiomas of the Lumbosacral SkinThe Journal of Pediatrics, 2010
- LUMBAR: Association between Cutaneous Infantile Hemangiomas of the Lower Body and Regional Congenital AnomaliesThe Journal of Pediatrics, 2010
- Orbit and eyelid hemangiomas: Is there a relationship between location and ocular problems?Journal of the American Academy of Dermatology, 2006
- Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distributionThe Journal of Pediatrics, 1997
- Guidelines of care for hemangiomas of infancyJournal of the American Academy of Dermatology, 1997
- Treatment of hemangiomas of infants with high doses of prednisoneThe Journal of Pediatrics, 1996